Multidrug resistance-related phenotype and apoptosis-related protein expression in ovarian serous carcinomas

Gynecologic Oncology

Volumn 100, Issue 1, 2006, Pages 152-159

  Yakirevich, Evgeny ^a,b   Sabo, Edmond ^a,b   Naroditsky, Inna ^a   Sova, Yanina ^a   Lavie, Ofer ^a   Resnick, Murray B ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

Bax; bcl 2; LRP; MDR; MRP1; Ovarian cancer; P gp; p53

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RELIABILITY;

EID: 29144461054     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.08.050     Document Type: Article

References (44)

1. A. Jemal, A. Thomas, T. Murray, and M. Thun Cancer statistics, 2002 CA Cancer J. Clin. 52 2002 23 47
2. C.H. Holschneider, and J.S. Berek Ovarian cancer: epidemiology, biology, and prognostic factors Semin. Surg. Oncol. 19 2000 3 10
3. M.M. Gottesman Mechanisms of cancer drug resistance Annu. Rev. Med. 53 2002 615 627
4. C.F. Haggins ABC transporters: from microorganisms to man Annu. Rev. Cell Biol. 8 1992 67 113
5. M.M. Gottesman, I. Pastan, and S.V. Ambudrak P-glycoprotein and multidrug resistance Curr. Opin. Genet. Dev. 6 1996 610 617
6. S.P. Cole, and R.G. Deeley Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP BioEssays 20 1998 931 940
7. P. Van der Valk, C.K. van Kalken, H. Ketelaars, H.J. Broxterman, G. Scheffer, and C.M. Kuiper Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule Ann. Oncol. 1 1990 56 64
8. M.J. Flens, G.J.R. Zaman, P. van der Valk, M.A. Izquierdo, A.B. Schroeijers, and G.L. Scheffer Tissue distribution of the multidrug resistance protein Am. J. Pathol. 148 1996 1237 1247
9. G.L. Scheffer, P.L.J. Wijngaard, M.J. Flens, M.A. Izquierdo, M.L. Slovak, and H.M. Pinedo The drug resistance-related protein LRP is the human major vault protein Nat. Med. 1 1995 578 582
10. M.A. Izquierdo, R.H. Shoemaker, M.J. Flens, G.L. Scheffer, L. Wu, and T.R. Prather Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines Int. J. Cancer 65 1996 230 237
11. M.A. Izquierdo, G.L. Scheffer, M.J. Flens, G. Giaccone, H.J. Broxterman, and C.J.L.M. Meijer Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors Am. J. Pathol. 148 1996 877 887
12. T. Schondorf, R. Neumann, C. Benz, M. Becker, M. Riffelmann, and U.J. Gohring Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines Recent Results Cancer Res. 161 2003 111 116
13. A.G. Van der Zee, H. Hollema, S. de Jong, H. Boonstra, A. Gouw, and P.H.B. Willemse P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy Cancer Res. 51 1991 5915 5920
14. S. Arao, H. Suwa, M. Mandai, H. Tashiro, K. Miyazaki, and H. Okamura Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer Cancer Res. 54 1994 1355 1359
15. A.G.J. Van der Zee, H.H. Hollema, A.J. Suurmeijer, M. Krans, W.J. Sluiter, and P.H.B. Willemse Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas J. Clin. Oncol. 13 1995 70 78
16. M.A. Izquierdo, A.G.J. van der Zee, J.B. Vermorken, P. van der Valk, J.A.M. Belien, and G. Giaccone Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognosis in advanced ovarian carcinoma J. Natl. Cancer Inst. 87 1995 1230 1237
17. H.J. Arts, D. Katsaros, E.G. de Vries, M. Massobrio, F. Genta, and S. Danese Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma Clin. Cancer Res. 5 1999 2798 2805
18. M. Kavallaris, J.A. Leary, J.A. Barrett, and M.L. Friedlander MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors Cancer Lett. 102 1996 7 16
19. T.A. Holzmayer, S. Hilsenbeck, D. Von, D. Hoff, and I.B. Roninson Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas J. Natl. Cancer Inst. 84 1992 1486 1491
20. F. Zhang, L. Qi, and H. Chen Value of P-glycoprotein and glutatione S-transferase-pi as chemoresistant indicators in ovarian cancers Zhonghua Zhongliu Zazhi 23 2001 313 316
21. J.A. Bush, and G. Li Cancer chemoresistance: the relationship between p53 and multidrug transporters Int. J. Cancer 98 2002 323 330
22. U. Martens, and U. Stenius Immunohistochemical detection of induced expression of wild-type p53 tumor suppressor protein in the livers of rats treated with diethylnitrosamine Histochem. J. 31 1999 75 78
23. F. Buttitta, A. Marchetti, A. Gadducci, S. Pellegrini, M. Morganti, and V. Carnicelli p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study Br. J. Cancer 75 1997 230 235
24. D. Debernardis, E.G. Sire, P. DeFeudis, F. Vikhanskaya, M. Valenti, and P. Russo p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel Cancer Res. 57 1997 870 874
25. C. Lavarino, S. Pilotti, M. Oggionni, L. Gatti, P. Perego, and G. Bresciani p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma J. Clin. Oncol. 18 2000 3936 3945
26. D.M. Hockenbery, G. Nuenz, C. Milliman, R.D. Schreber, and S.J. Korsmeyer Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death Nature 348 1990 334 336
27. T. Miyashita, and J.C. Reed bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs Cancer Res. 52 1992 5407 5411
28. T. Strobel, L. Swanson, S. Korsmeyer, and S.A. Cannistra BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway Proc. Natl. Acad. Sci. U. S. A. 93 1996 14094 14099
29. A.J. Zurita, J.E. Diestra, E. Condom, X. Garcia Del Muro, G.L. Scheffer, and R.J. Scheper Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours Br. J. Cancer 88 2003 879 886
30. W.T. Beck, T. Grogan, C.L. Willman, C. Cordon-Cardo, D.M. Parham, and J.F. Kuttecsch Methods to detect P-glycoprotein-associated multidrug resistance in patients tumors: consensus recommendations Cancer Res. 56 1996 3010 3020
31. M. Schuyer, M.E. van der Burg, S.C. Henzen-Logmans, J.H. Fieret, J.G. Klijn, and M.P. Look Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2 Br. J. Cancer 85 2001 (Nov. 2) 1359 1367
32. Y.T. Tai, S. Lee, E. Niloff, C. Weisman, T. Strobel, and S.A. Cannistra BAX protein expression and clinical outcome in epithelial ovarian cancer J. Clin. Oncol. 16 1998 2583 2590
33. R.S. Weinstein, S.M. Jakate, J.M. Dominguez, M.D. Lebovitz, G.K. Koukoulis, and G.R. Kuszak Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastases Cancer Res. 51 1991 2720 2726
34. J. Wallner, D. Depisch, M. Hopfner, K. Haider, J. Spona, and H. Ludwig MDR1 gene expression and prognostic factors in primary breast carcinomas Eur. J. Cancer 11 1991 1352 1355
35. N. Baldini, K. Scotlandi, G. Barbanti-Brodano, M.C. Manara, D. Maurici, and G. Bacci Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome N. Engl. J. Med. 333 1995 1380 1385
36. M. Michieli, D. Damiani, A. Ermacora, P. Masolini, D. Raspadori, and G. Visani P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukemias: biological and clinical implications Br. J. Haematol. 104 1999 328 335
37. V. Materna, J. Pleger, U. Hoffmann, and H. Lage RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response Gynecol. Oncol. 94 2004 152 160
38. K. Ikeda, K. Sakai, R. Yamamoto, H. Hareyama, N. Tsumura, and H. Watari Multivariate analysis for prognostic significance of histologic subtype, GST-pi, MDR-1, and p53 in stages II-IV ovarian cancer Int. J. Gynecol. Cancer 13 2003 776 784
39. Y. Ohishi, Y. Oda, T. Uchiumi, H. Kobayashi, T. Hirakawa, and S. Miyamoto ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma Clin. Cancer Res. 8 2002 3767 3775
40. S. Kamazawa, J. Kigawa, Y. Kanamori, H. Itamochi, S. Sato, and T. Iba Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer Gynecol. Oncol. 86 2002 171 176
41. R.T. Penson, E. Oliva, S.J. Skates, T. Glyptis, A.F. Fuller Jr, and A. Goodman Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples Gynecol. Oncol. 3 2004 98 106
42. S.W. Johnson, R.P. Perez, A.K. Godwin, A.T. Yeung, L.M. Handel, and R.F. Ozols Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines Biochem. Pharmacol. 47 1994 689 697
43. Z. Duan, Y. Duan, D.E. Lamendola, R.Z. Yusuf, R. Naeem, and R.T. Penson Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines Clin. Cancer Res. 9 2003 2778 2785
44. E. Yakirevich, E. Sabo, O. Lavie, S. Mazareb, G.C. Spagnoli, and M.B. Resnick Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms Clin. Cancer Res. 9 2003 6453 6460